Last reviewed · How we verify
Nature Cell Co. Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Synvisc-One | Synvisc-One | marketed | Viscosupplement; hyaluronic acid derivative | Synovial fluid; joint cartilage surfaces | Orthopedics; Rheumatology |
Therapeutic area mix
- Orthopedics; Rheumatology · 1
- Regenerative medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Gary A Levy, O. Ont. MD. FRCP AGAF · 1 shared drug class
- Gwo Xi Stem Cell Applied Technology Co., Ltd. · 1 shared drug class
- Manipal Acunova Ltd. · 1 shared drug class
- Mesoblast, Inc. · 1 shared drug class
- Tigenix S.A.U. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nature Cell Co. Ltd.:
- Nature Cell Co. Ltd. pipeline updates — RSS
- Nature Cell Co. Ltd. pipeline updates — Atom
- Nature Cell Co. Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nature Cell Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nature-cell-co-ltd. Accessed 2026-06-09.